Fruquintinib CYP3A Inhibitor and Inducer Study
Condition(s):Drug Drug InteractionLast Updated:June 18, 2021Completed
Hide Studies Not Open or Pending
Condition(s):Drug Drug InteractionLast Updated:June 18, 2021Completed
Condition(s):B-cell MalignanciesLast Updated:November 27, 2023Completed
Condition(s):Relapsed or Refractory LymphomaLast Updated:March 6, 2024Completed
Condition(s):HealthyLast Updated:February 3, 2021Completed
Condition(s):CYP3A Inhibitor; Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer; Pancreatic Adenocarcinoma; Pancreatic NeoplasmLast Updated:February 23, 2024Recruiting
Condition(s):Diffuse Large B Cell Lymphoma; Primary Mediastinal Lymphoma; Mantle Cell Lymphoma; Advanced Solid Tumor; Marginal Zone LymphomaLast Updated:June 26, 2023Completed
Condition(s):Chronic Hepatitis CLast Updated:January 11, 2016Completed
Condition(s):Drug Interaction Potentiation; HealthyLast Updated:February 22, 2018Completed
Condition(s):Neoplasm MetastasisLast Updated:December 11, 2023Completed
Condition(s):B-Cell Chronic Lymphocytic LeukemiaLast Updated:June 26, 2017Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.